Goh Brian Kp, Lee Ser-Yee, Chan Chung-Yip, Wong Jen-San, Cheow Peng-Chung, Chung Alexander Yf, Ooi London Lpj
Department of Hepatopancreatobiliary and Transplantation Surgery, Singapore General Hospital, Singapore.
Duke-NUS Medical School, Singapore.
Singapore Med J. 2018 Mar;59(3):133-138. doi: 10.11622/smedj.2017092. Epub 2017 Oct 6.
Experience with robot-assisted laparoscopic (RAL) hepatobiliary and pancreatic (HPB) surgery remains limited worldwide. In this study, we report our early experience with RAL HPB surgery in Singapore.
A retrospective review of the first 20 consecutive patients who underwent RAL HPB surgery at a single institution over a 34-month period from February 2013 to November 2015 was conducted. The 20 cases were performed by three principal surgeons, of which 17 (85.0%) were performed by a single surgeon.
The median age of patients was 56 (range 22-75) years and median tumour size was 4.0 (range 1.2-7.5) cm. The surgeries performed included left-sided pancreatectomies (n = 10), hepatectomies (n = 7), triple bypass with bile duct exploration for obstructing pancreatic head cancer with choledocholithiasis (n = 1), cholecystectomy for Mirizzi's syndrome (n = 1) and gastric resection for gastrointestinal stromal tumour (n = 1). The median operation time was 445 (range 80-825) minutes and median blood loss was 350 (range 0-1,200) mL. There was only 1 (5%) open conversion. There were 2 (10.0%) major morbidities (> Grade II on the Clavien-Dindo classification) and no 30-day/in-hospital mortalities. There was no reoperation for postoperative complications. The median postoperative stay was 5.5 (range 3-22) days.
Our initial experience confirms the feasibility and safety of RAL HPB surgery.
机器人辅助腹腔镜(RAL)肝胆胰(HPB)手术在全球范围内的经验仍然有限。在本研究中,我们报告了我们在新加坡开展RAL HPB手术的早期经验。
对2013年2月至2015年11月期间在单一机构连续接受RAL HPB手术的前20例患者进行回顾性研究。这20例手术由三位主刀医生完成,其中17例(85.0%)由一位医生完成。
患者的中位年龄为56岁(范围22 - 75岁),肿瘤中位大小为4.0 cm(范围1.2 - 7.5 cm)。所进行的手术包括左侧胰腺切除术(n = 10)、肝切除术(n = 7)、因胆总管结石梗阻性胰头癌行三联搭桥及胆管探查术(n = 1)、Mirizzi综合征胆囊切除术(n = 1)以及胃肠道间质瘤胃切除术(n = 1)。中位手术时间为445分钟(范围80 - 825分钟),中位失血量为350 mL(范围0 - 1200 mL)。仅1例(5%)转为开腹手术。有2例(10.0%)严重并发症(Clavien - Dindo分类> II级),无30天/住院期间死亡病例。术后并发症未进行再次手术。中位术后住院时间为5.5天(范围3 - 22天)。
我们的初步经验证实了RAL HPB手术的可行性和安全性。